Avalon Pharmaceuticals Appoints Bradley G. Lorimier Chairman of Board of Directors
06 August 2007 - 10:00PM
PR Newswire (US)
- Alan G. Walton, Ph.D., D.Sc., will remain as Director -
GERMANTOWN, Md., Aug. 6 /PRNewswire-FirstCall/ -- Avalon
Pharmaceuticals, Inc. (NASDAQ:AVRX), today announced the
appointment of Bradley G. Lorimier as Chairman of the Board of
Directors. He succeeds Alan G. Walton, Ph.D., D.Sc., who will stay
on as a Director. "We are delighted with the appointment of Brad
Lorimier to Chairman of the Avalon Board," said Kenneth C. Carter,
Ph.D., President and CEO of Avalon Pharmaceuticals. "His extensive
industry experience and work with the Company since our beginning
has proved invaluable to our success and we look forward to his
leadership in this new role. We are also deeply grateful and
indebted to the vision and leadership provided to the Company by
Alan Walton and we look forward to his continued contributions in
the years ahead." Bradley G. Lorimier is a co-founder of Avalon and
has served as a member of the Board of Directors since December
1999. "I am delighted to accept the chairmanship and look forward
to working with the Board of Directors to help the Avalon
management team as they continue to grow the company," said Mr.
Lorimier. Currently, Mr. Lorimier is a member of the Board of
Directors for Invitrogen Corporation and was its past Chairman. Mr.
Lorimier is also a Board member for several private venture backed
companies and was a past director of Matrix Pharmaceutical, Inc.
Since 1997, he has been an independent consultant to the
pharmaceutical and biotechnology industries and prior to that had a
long and distinguished business career with several Fortune 500
companies. In 1997 Brad retired as the Senior Vice President of
Business Development and Member of the Board of Directors for Human
Genome Sciences (HGS). Prior to that, Mr. Lorimier held positions
of increasing responsibility at Johnson & Johnson where he was
Vice President of Licensing for the Pharmaceutical Sector, Vice
President of Corporate Development for Ortho McNeil and Member of
the Management Committee and Executive Committee Member of the R.W.
Johnson Pharmaceutical Research Institute. Prior to Johnson &
Johnson, Brad held Senior Management positions with Sterling Drugs
and Revlon Health Care. Mr. Lorimier received his B.S. from the
University of Illinois in 1967. About Avalon Pharmaceuticals Avalon
is a biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class cancer
therapeutics. Avalon's lead product candidate, AVN944, an IMPDH
inhibitor, is in Phase II clinical development. Avalon also has
preclinical programs to develop inhibitors of the Beta-catenin and
Aurora pathways, discovery programs for inhibitors of the survivin
and Myc pathways and partnerships with Merck, MedImmune, Medarex,
and Novartis. AvalonRx(R) is the company's proprietary platform
which is based on large-scale biomarker identification and
monitoring, used to discover and develop therapeutics for pathways
that have historically been characterized as "undruggable." Avalon
is headquartered in Germantown, Md. Contacts: Avalon
Pharmaceuticals, Inc. Russo Partners, LLC David D. Muth Wendy Lau
(Media) Executive Vice President & Tel: (212) 845-4272 Chief
Business Officer Tel: (301) 556-9900 The Trout Group LLC Fax: (301)
556-9910 Chad Rubin (Investors) Email: Tel: (646) 378-2947
DATASOURCE: Avalon Pharmaceuticals, Inc. CONTACT: David D. Muth,
Executive Vice President & Chief Business Officer of Avalon
Pharmaceuticals, Inc., +1-301-556-9900, or Fax, +1-301-556-9910, or
; or Media, Wendy Lau of Russo Partners, LLC, +1-212-845-4272; or
Investors, Chad Rubin of The Trout Group LLC, +1-646-378-2947
Copyright
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Avalon Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More Avalon Pharmaceuticals (MM) News Articles